Pfizer-BioNTech Adapted Bivalent Booster Neutralizes Emerging Omicron Subvariants

Article

New clinical findings suggest the Pfizer-BioNTech bivalent booster elicited more neutralizing antibody titers for all tested emerging Omicron sublineages, compared to their original COVID-19 vaccine.

New clinical findings suggest the Pfizer-BioNTech bivalent booster elicited a more neutralizing antibody titers for all tested emerging Omicron sublineages, compared to their original COVID-19 vaccine.

This week, Pfizer-BioNTech shared positive results from an immune response analysis of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. The findings suggest that the bivalent booster is effective against newer Omicron sublineages, including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1.

At 1 month after a 30-µg booster dose of Pfizer-BioNTech’s updated bivalent vaccine, Omicron BA.4/BA.5 neutralizing antibody titers increased 13.2-fold in in adults older than 55 years, and 9.5-fold in adults 18-55 years.

Pfizer-BioNTech shared these data on the preprint server bioRxiv. With these results, the biotech companies concluded that their bivalent vaccine elicits a greater increase in neutralizing antibodies against emerging Omicron subvariants than their original wild-type COVID-19 vaccine.

The results showed that after a booster dose of the Pfizer-BioNTech Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibodies against BA.4.6 increased 11.1-fold (95% CI: 7.1, 17.3), 6.7-fold (95% CI: 4.4,10.2) against BA.2.75.2, 8.7-fold (95% CI: 5.7, 13.3) against BQ.1.1, and 4.8-fold (95% CI: 3.3, 6.9) against XBB.1.

Comparatively, with the original Pfizer-BioNTech COVID-19 booster vaccine, neutralizing antibodies against BA.4.6 increased 2.3-fold (95% CI: 1.9, 2.8), 2.1-fold (95% CI: 1.7, 2.5) against BA.2.75.2, 1.8-fold, (95% CI: 1.6, 2.2) against BQ.1.1, and 1.5-fold (95% CI: 1.3, 1.8) against XBB.1.

Notably, the safety and tolerability profiles of the bivalent booster are comparably favorable to the original Pfizer-BioNTech COVID-19 vaccine.

These findings are similar to earlier clinical data suggesting Pfizer-BioNTech’s bivalent booster produced a 13.2-fold increase in BA.4/BA.5 antibody titers, compared to pre-boosting levels, in persons 55 years and older. This evoked a BA.4/BA.5 response 4-fold higher than the original Pfizer-BioNTech vaccine.

Currently, a booster dose of Pfizer-BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine is available for individuals 5 years and older under Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA).

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.